![MPP signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir](https://mv.ecuo.org/wp-content/uploads/sites/4/2018/11/3022051-15248012599296756_origin-270x189_c.jpg)
MPP signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir
The Medicines Patent Pool (MPP) has announced a new, royalty-free licence agreement with AbbVie for glecaprevir/pibrentasvir (G/P) – a World Health Organization (WHO)-recommended treatment for people living with chronic hepatitis C (HCV).